Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Simulations Plus has a consensus analyst recommendation of Hold from 10 firms (1 sell, 6 hold, 3 buy) with an average 12‑month price target of $24.40.
• The company beat Q1 estimates—$0.35 EPS vs $0.27 and $24.29M revenue vs $21.66M—but still reported a negative net margin of 77.96% and a negative P/E (-4.65), highlighting profitability concerns despite the beat.
• Shares opened at $14.56 (12‑month range $11.09–$36.20) with a market cap of about $294M, and institutional investors hold roughly 78% of the stock.

Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) has earned a consensus recommendation of "Hold" from the ten research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $24.40.

SLP has been the subject of a number of analyst reports. Zacks Research downgraded shares of Simulations Plus from a "strong-buy" rating to a "hold" rating in a report on Monday, February 2nd. Wall Street Zen downgraded shares of Simulations Plus from a "buy" rating to a "hold" rating in a report on Saturday, April 4th. Citigroup reaffirmed a "market perform" rating on shares of Simulations Plus in a report on Tuesday, January 6th. Finally, TD Cowen lowered their price target on shares of Simulations Plus from $19.00 to $16.00 and set a "hold" rating for the company in a report on Friday, April 10th.

Simulations Plus Stock Performance

Shares of NASDAQ:SLP opened at $14.56 on Monday. Simulations Plus has a 12 month low of $11.09 and a 12 month high of $36.20. The company has a 50-day moving average price of $12.53 and a 200 day moving average price of $15.89. The company has a market cap of $294.11 million, a price-to-earnings ratio of -4.65 and a beta of 1.19.

Simulations Plus (NASDAQ:SLP - Get Free Report) last announced its quarterly earnings results on Thursday, April 9th. The technology company reported $0.35 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.08. Simulations Plus had a negative net margin of 77.96% and a positive return on equity of 16.21%. The firm had revenue of $24.29 million during the quarter, compared to the consensus estimate of $21.66 million. As a group, equities analysts forecast that Simulations Plus will post 1.03 EPS for the current year.

Institutional Trading of Simulations Plus

Several institutional investors have recently added to or reduced their stakes in the company. SOL Capital Management CO bought a new stake in Simulations Plus in the first quarter worth about $165,000. North Star Investment Management Corp. lifted its stake in Simulations Plus by 17.4% in the first quarter. North Star Investment Management Corp. now owns 197,330 shares of the technology company's stock worth $2,332,000 after purchasing an additional 29,200 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in Simulations Plus in the first quarter worth about $130,000. Corient Private Wealth LLC bought a new stake in Simulations Plus in the fourth quarter worth about $397,000. Finally, Caitong International Asset Management Co. Ltd lifted its stake in Simulations Plus by 343.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,983 shares of the technology company's stock worth $73,000 after purchasing an additional 3,084 shares during the last quarter. Institutional investors own 78.08% of the company's stock.

Simulations Plus Company Profile

Simulations Plus, Inc NASDAQ: SLP specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company's flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.